<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679870</url>
  </required_header>
  <id_info>
    <org_study_id>MYLOX-1</org_study_id>
    <secondary_id>2020-003087-45</secondary_id>
    <nct_id>NCT04679870</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis</brief_title>
  <official_title>An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galecto Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OPIS s.r.l</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galecto Biotech AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, phase IIa trial in subjects with Myelofibrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of orally administered GB2064 a LOXL-2 inhibitor over 9 months. Subjects&#xD;
      will receive doses of GB2064, given twice per day to participants with primary or secondary&#xD;
      Myelofibrosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects eligible for the study will receive GB2064 1000mg, twice a day</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of GB2064: AE</measure>
    <time_frame>9 Months</time_frame>
    <description>Incidence and severity of adverse events as reported by investigators</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>GB2064</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB2064 will be administered orally as 4 x 250 mg tablets twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB2064</intervention_name>
    <description>GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day</description>
    <arm_group_label>GB2064</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must satisfy all of the following criteria at the Screening visit:&#xD;
&#xD;
          1. Adult male or female participants ≥ 18 years of age at enrolment:&#xD;
&#xD;
               1. Female participants may be of non-childbearing potential defined as permanently&#xD;
                  sterile or postmenopausal, or female participants considered to be of&#xD;
                  childbearing potential who agree to use highly effective birth control methods&#xD;
                  until 90 days after the follow-up visit. Female participants should refrain from&#xD;
                  ova donation from the date of Enrolment (Day -1) until 90 days after the&#xD;
                  follow-up visit.&#xD;
&#xD;
               2. Male participants will agree to use contraception throughout the study and until&#xD;
                  90-days after the Follow-up visit. Male participants must agree to refrain from&#xD;
                  sperm donation from the date of Enrolment (Day -1) until 90 days after the&#xD;
                  follow-up visit.&#xD;
&#xD;
          2. Diagnosis of PMF or SMF with intermediate -2 or high-risk disease according to the&#xD;
             Dynamic International Prognostic Scoring System (DIPSS)-plus or if with low risk&#xD;
             disease then with symptomatic splenomegaly as defined by sonographic assessment as&#xD;
             spleen length of &gt;12 cm or by physical examination as ≥ 5 cm below left costal margin.&#xD;
&#xD;
          3. Participants who are not currently taking a Janus kinase (JAK) inhibitor (e.g.&#xD;
             ruxolitinib or fedratinib) and are therefore refractory, intolerant or ineligible for&#xD;
             a JAK inhibitor according to appropriate guidelines (including local guidelines).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
          5. Required baseline laboratory status:&#xD;
&#xD;
               1. Absolute platelet count (APC) ≥ 50 x 109/L&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/mm3)&#xD;
&#xD;
               3. Serum direct bilirubin ≤ 2.0 x ULN (upper limit of normal)&#xD;
&#xD;
               4. AST (SGOT) or ALT (SGPT) [if both measured, then this applies to both&#xD;
                  measurements] ≤ 2.5 x ULN, except for participants with MF involvement of the&#xD;
                  liver who must have levels ≤ 5 x ULN&#xD;
&#xD;
               5. Estimated Glomerular Filtration Rate (eGFR) or creatinine clearance (CrCl) (CrCl&#xD;
                  calculated by the Cockroft and Gault method) ≥ 30 ml/min/1.73 m2.&#xD;
&#xD;
               6. Peripheral blood blasts &lt;10%&#xD;
&#xD;
          6. Treatment-related toxicities from prior therapies must have resolved to Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1.&#xD;
&#xD;
          7. Participants must have a documented history of transfusion records (if there have been&#xD;
             any such transfusions) in the preceding 12 weeks to Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current treatment with a JAK inhibitor (e.g. ruxolitinib or fedratinib) or a history&#xD;
             of treatment with a JAK inhibitor within two weeks of enrolment.&#xD;
&#xD;
          2. Positive hepatitis panel and/or positive HIV test.&#xD;
&#xD;
          3. Any concurrent severe and/or uncontrolled medical conditions that could increase the&#xD;
             participant's risk for toxicity while in the study or that could confound&#xD;
             discrimination between disease- and study treatment-related toxicities. Any planned&#xD;
             major surgery during the study period&#xD;
&#xD;
          4. Impaired cardiac function or clinically significant cardiac diseases, including any of&#xD;
             the following:&#xD;
&#xD;
               1. History or presence of ventricular tachyarrhythmia.&#xD;
&#xD;
               2. Presence of unstable atrial fibrillation (ventricular response &gt; 100 bpm);&#xD;
                  Participants with stable atrial fibrillation are eligible, provided they do not&#xD;
                  meet any of the other cardiac exclusion criteria.&#xD;
&#xD;
               3. Clinically significant resting bradycardia (&lt; 50 bpm) and use of a cardiac&#xD;
                  pacemaker or implantable cardioverter defibrillator.&#xD;
&#xD;
               4. Angina pectoris or acute myocardial infarction ≤ 90 days prior to starting study&#xD;
                  drug.&#xD;
&#xD;
               5. Other clinically significant heart disease (e.g., symptomatic congestive heart&#xD;
                  failure; uncontrolled arrhythmia or hypertension; history of labile hypertension&#xD;
                  or poor compliance with an antihypertensive regimen).&#xD;
&#xD;
          5. Participants who are currently receiving chronic (&gt; 14 days) treatment with&#xD;
             corticosteroids at a dose &gt; 10 mg of prednisone (or its glucocorticoid equivalent) per&#xD;
             day, or any other chronic immunosuppressive treatment that cannot be discontinued&#xD;
             prior to starting study drug.&#xD;
&#xD;
          6. Participants with impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of GB2064 as per physician's opinion.&#xD;
&#xD;
          7. Participants who received radiotherapy within the last month prior to screening&#xD;
             procedures, or patients who received splenectomy in the previous three months or are&#xD;
             scheduled for the procedure in the next three months.&#xD;
&#xD;
          8. Participants who had a history of malignancy in the past 3 years, except for treated&#xD;
             early stage squamous, basal cell carcinoma or treated, localised prostate cancer.&#xD;
&#xD;
          9. Presence of clinically meaningful active bacterial, fungal, parasitic or viral&#xD;
             infection which requires therapy.&#xD;
&#xD;
         10. Previous history of Progressive Multifocal Leuko-encephalopathy (PML).&#xD;
&#xD;
         11. Pregnant or breast feeding (lactating) women, where pregnancy is defined as the state&#xD;
             of a female after conception and until the termination of gestation, confirmed by a&#xD;
             positive β- HCG laboratory test.&#xD;
&#xD;
         12. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             during dosing and for 90 days after study treatment. Highly effective contraception&#xD;
             methods must be used.&#xD;
&#xD;
         13. Sexually active males must use a condom during intercourse while taking the drug and&#xD;
             for 90 days after stopping study drug and should not father a child in this period. A&#xD;
             condom is required to be used also by vasectomized men in order to prevent delivery of&#xD;
             the drug via seminal fluid.&#xD;
&#xD;
         14. Hypersensitivity to GB2064 and/or its excipients.&#xD;
&#xD;
         15. Participants unable or unwilling to comply with protocol requirements.&#xD;
&#xD;
         16. Participants related to PI/site staff.&#xD;
&#xD;
         17. Participants who have had a hematopoietic stem cell transplantation.&#xD;
&#xD;
         18. Participants who are eligible, have a donor and are willing to undergo a hematopoietic&#xD;
             stem cell transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srdan Verstovsek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertil Lindmark, MD</last_name>
    <phone>+4570705210</phone>
    <email>Clinicaltrials@galecto.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Andersson Cancer Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srdan Verstovsek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology</name>
      <address>
        <city>Canberra</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dipti Talaulikar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine-University Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Gattermann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Schlenk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg-Nikolaus Franke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Haemathologie and Onkologie am Isartor</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petro Petrides, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universitaet Munchen</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Herhaus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Bologna Sant Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Palandri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Mannelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Caramella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Cilloni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio-Sanitaria Territoriale dei Sette Laghi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Passamonti, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GB2064</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>LOXL-2</keyword>
  <keyword>PAT1251</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

